These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 18625599)

  • 1. Critical issue is rapidity of review of new drugs.
    Rodger A
    BMJ; 2008 Jul; 337(7662):a779. PubMed ID: 18625599
    [No Abstract]   [Full Text] [Related]  

  • 2. Drugs for cancer and copayments.
    Finlay I; Crisp N
    BMJ; 2008 Jun; 337(7660):a527. PubMed ID: 18595953
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Paying for cancer care - a new dilemma.
    Sikora K
    J R Soc Med; 2007 Apr; 100(4):166-9. PubMed ID: 17404337
    [No Abstract]   [Full Text] [Related]  

  • 4. Overspending driven by oversized single dose vials of cancer drugs.
    Bach PB; Conti RM; Muller RJ; Schnorr GC; Saltz LB
    BMJ; 2016 Feb; 352():i788. PubMed ID: 26932932
    [No Abstract]   [Full Text] [Related]  

  • 5. News feature: Costly US anticancer drugs pose problems for doctors and patients.
    Charatan F
    BMJ; 2008 Jul; 337(7662):a778. PubMed ID: 18625596
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs.
    Tefferi A; Kantarjian H; Rajkumar SV; Baker LH; Abkowitz JL; Adamson JW; Advani RH; Allison J; Antman KH; Bast RC; Bennett JM; Benz EJ; Berliner N; Bertino J; Bhatia R; Bhatia S; Bhojwani D; Blanke CD; Bloomfield CD; Bosserman L; Broxmeyer HE; Byrd JC; Cabanillas F; Canellos GP; Chabner BA; Chanan-Khan A; Cheson B; Clarkson B; Cohn SL; Colon-Otero G; Cortes J; Coutre S; Cristofanilli M; Curran WJ; Daley GQ; DeAngelo DJ; Deeg HJ; Einhorn LH; Erba HP; Esteva FJ; Estey E; Fidler IJ; Foran J; Forman S; Freireich E; Fuchs C; George JN; Gertz MA; Giralt S; Golomb H; Greenberg P; Gutterman J; Handin RI; Hellman S; Hoff PM; Hoffman R; Hong WK; Horowitz M; Hortobagyi GN; Hudis C; Issa JP; Johnson BE; Kantoff PW; Kaushansky K; Khayat D; Khuri FR; Kipps TJ; Kripke M; Kyle RA; Larson RA; Lawrence TS; Levine R; Link MP; Lippman SM; Lonial S; Lyman GH; Markman M; Mendelsohn J; Meropol NJ; Messinger Y; Mulvey TM; O'Brien S; Perez-Soler R; Pollock R; Prchal J; Press O; Radich J; Rai K; Rosenberg SA; Rowe JM; Rugo H; Runowicz CD; Sandmaier BM; Saven A; Schafer AI; Schiffer C; Sekeres MA; Silver RT; Siu LL; Steensma DP; Stewart FM; Stock W; Stone R; Storb R; Strong LC; Tallman MS; Thompson M; Ueno NT; Van Etten RA; Vose JM; Wiernik PH; Winer EP; Younes A; Zelenetz AD; LeMaistre CA
    Mayo Clin Proc; 2015 Aug; 90(8):996-1000. PubMed ID: 26211600
    [No Abstract]   [Full Text] [Related]  

  • 7. Why not adopt the blacklist of yore?
    Lewis LS
    BMJ; 2008 Jul; 337(7662):a807. PubMed ID: 18625603
    [No Abstract]   [Full Text] [Related]  

  • 8. Cancer Drugs Fund of minimal benefit.
    Burki TK
    Lancet Oncol; 2017 Jun; 18(6):e305. PubMed ID: 28483412
    [No Abstract]   [Full Text] [Related]  

  • 9. New "managed access" process for Cancer Drugs Fund to go ahead, NHS England confirms.
    Mayor S
    BMJ; 2016 Feb; 352():i1208. PubMed ID: 26926879
    [No Abstract]   [Full Text] [Related]  

  • 10. NHS will not pay for drugs that offer little clinical benefit, says cancer fund boss.
    Kmietowicz Z
    BMJ; 2015 Jan; 350():h125. PubMed ID: 25569117
    [No Abstract]   [Full Text] [Related]  

  • 11. Oncology drug pricing structure is broken.
    Hutchinson L
    Nat Rev Clin Oncol; 2015 Sep; 12(9):499. PubMed ID: 26309071
    [No Abstract]   [Full Text] [Related]  

  • 12. Lowering the High Cost of Cancer Drugs--I.
    Braillon A
    Mayo Clin Proc; 2016 Mar; 91(3):397. PubMed ID: 26944245
    [No Abstract]   [Full Text] [Related]  

  • 13. In Reply--Lowering the High Cost of Cancer Drugs.
    Kantarjian H; Tefferi A
    Mayo Clin Proc; 2016 Mar; 91(3):401-3. PubMed ID: 26944248
    [No Abstract]   [Full Text] [Related]  

  • 14. Lowering the High Cost of Cancer Drugs--III.
    Attaran A; Mackey T; Beall R
    Mayo Clin Proc; 2016 Mar; 91(3):399-400. PubMed ID: 26944246
    [No Abstract]   [Full Text] [Related]  

  • 15. Lowering the High Cost of Cancer Drugs--IV.
    Martenson JA
    Mayo Clin Proc; 2016 Mar; 91(3):400-1. PubMed ID: 26944247
    [No Abstract]   [Full Text] [Related]  

  • 16. [Pharmacoeconomic aspects of oral cytostatic agents].
    Poquet Jornet JE; Carrera-Hueso FJ; Gasent Blesa JM; Peris Godoy M
    Farm Hosp; 2011 May; 35 Suppl 2():25-31. PubMed ID: 22445506
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cancer Drugs Fund 2.0: A Missed Opportunity?
    McCabe C; Paul A; Fell G; Paulden M
    Pharmacoeconomics; 2016 Jul; 34(7):629-33. PubMed ID: 27002519
    [No Abstract]   [Full Text] [Related]  

  • 18. A question of health. The lottery of cancer care.
    Health Serv J; 1997 Dec; 107(5584):suppl 1-4 following 24. PubMed ID: 10184833
    [No Abstract]   [Full Text] [Related]  

  • 19. US oncologists call for government regulation to curb drug price rises.
    McCarthy M
    BMJ; 2015 Jul; 351():h4063. PubMed ID: 26208848
    [No Abstract]   [Full Text] [Related]  

  • 20. NHS England pulls funding from 25 cancer treatments.
    Kmietowicz Z
    BMJ; 2015 Jan; 350():h214. PubMed ID: 25588769
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.